Results 341 to 350 of about 1,334,419 (369)
Some of the next articles are maybe not open access.
Cellular Immunology, 1984
A temporal study assessed the relationship between fibrosarcoma growth and immunologic encumbrance due to the inability of BALB/c mouse splenocytes to elaborate the lymphokine Interleukin 2 (IL-2). Nylon-wool fractionation and antiserum treatments suggested the existence of a mildly nylon-wool-adherent, anti-Lyt 2-sensitive tumor-induced suppressor T ...
Burger, C J, Elgert, K D, Farrar, W L
openaire +2 more sources
A temporal study assessed the relationship between fibrosarcoma growth and immunologic encumbrance due to the inability of BALB/c mouse splenocytes to elaborate the lymphokine Interleukin 2 (IL-2). Nylon-wool fractionation and antiserum treatments suggested the existence of a mildly nylon-wool-adherent, anti-Lyt 2-sensitive tumor-induced suppressor T ...
Burger, C J, Elgert, K D, Farrar, W L
openaire +2 more sources
Cellular Immunology, 1985
Due to its purity and potential availability in large amounts, human recombinant interleukin 2 (IL-2) expressed in Escherichia coli is an important source of IL-2 for experimentation and possible therapy. To date, very few comparisons between the activity of recombinant IL-2 and conventional cell-derived preparations of IL-2 have been made.
C M, Roifman +3 more
openaire +2 more sources
Due to its purity and potential availability in large amounts, human recombinant interleukin 2 (IL-2) expressed in Escherichia coli is an important source of IL-2 for experimentation and possible therapy. To date, very few comparisons between the activity of recombinant IL-2 and conventional cell-derived preparations of IL-2 have been made.
C M, Roifman +3 more
openaire +2 more sources
European Journal of Cancer, 1994
Serum samples from 217 cancer patients participating in phase I/II clinical trials were analysed for the development of anti-interleukin-2 (IL-2) antibodies. Patients received recombinant human IL-2 (rIL-2) by continuous intravenous infusion (c.i.v.; n = 86) or by subcutaneous (s.c.) injections (n = 131).
J G, Scharenberg +7 more
openaire +2 more sources
Serum samples from 217 cancer patients participating in phase I/II clinical trials were analysed for the development of anti-interleukin-2 (IL-2) antibodies. Patients received recombinant human IL-2 (rIL-2) by continuous intravenous infusion (c.i.v.; n = 86) or by subcutaneous (s.c.) injections (n = 131).
J G, Scharenberg +7 more
openaire +2 more sources
[Interleukin-2 (IL-2) in active pulmonary tuberculosis].
Kekkaku : [Tuberculosis], 1992To clarify the precise of cellular immunity mechanism in pulmonary tuberculosis, we investigated the amount of IL-2 in patients with untreated active pulmonary tuberculosis. When serum adenosine deaminase (ADA) activity was examined using enzyme assay, an abnormally high level was observed in all patients (29.0 + 11.6 IU/ml, mean + SD; 4.5-17.8, normal
T, Ida +8 more
openaire +1 more source
Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4.
Science, 1993M. Kondo +6 more
semanticscholar +1 more source
Antibodies to Interleukin-2 (IL-2) in Patients: Cross Reactivity with Different IL-2 Species
1990Nautral interleukin-2 (nIL-2) is a polypeptide which is synthesized and secreted in a nonglycosylated as well as in two glycosylated species. The lymphokine regulates growth and differentiation of lymphocytes. It is produced by T lymphocytes upon antigenic or mitogenic stimulation.
H. Mohr +4 more
openaire +1 more source
Interleukin-2 (IL-2, Proleukin) and immune function.
Project Inform perspective, 2003IL-2 is an immune-based therapy that results in dramatic increases in CD4+ cell counts when used in conjunction with anti-HIV therapy. Although IL-2 has been discussed in previous issues of PI Perspective, new information warrants a further look at the product.
openaire +1 more source